Please login to the form below

Not currently logged in
Email:
Password:

AZ, Amgen’s investigational asthma drug comes good in phase 3

Tezepelumab evaluated in late-stage trial of severe asthma patients

An experimental asthma drug co-developed by AstraZeneca (AZ) and Amgen significantly reduces the annualised asthma exacerbation rate (AAER) in patients with severe, uncontrolled asthma.

The investigational medicine, tezepelumab, is a thymic stromal lymphopoietin (TSLP) targeting antibody – TLSP is thought to play a pivotal role in causing asthma inflammation and is a novel target for an asthma drug.

The phase 3 NAVIGATOR trial evaluated tezepelumab plus standard of care, which included medium- or high-dose inhaled corticosteroids (ICS) plus at least one controller medication, with or without oral corticosteroids (OCS).

Over 52 weeks, tezepelumab hit the primary endpoint of the trial after demonstrating a statistically significant and clinically meaningful reduction in AAER.

In addition, a subgroup of patients with baseline eosinophil (a type of white blood cell) counts under 300 cells per microlite who were treated with the drug also achieved meaningful reductions in AAER.

Another patient subgroup containing participants with baseline eosinophils under 150 cells per microlite experienced similar reductions in AAER.

In September 2018, tezepelumab scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) in patients with severe asthma without an eosinophilic phenotype.

AZ and Amgen’s drug acts further upstream in the inflammatory cascade responsible for asthma, which could help it to become a new standard treatment for severe asthma patients with low eosinophil levels.

According to AZ, over two-thirds of patients with severe asthma have T2 inflammation-driven asthma, which includes the eosinophilic phenotype, and typically elevated eosinophil levels.

“Tezepelumab works differently from any other asthma biologic medicine and targets multiple inflammatory pathways that contribute to asthma symptoms and exacerbations,” said Mene Pangalos, executive vice president, BioPharmaceuticals R&D at AZ.

“Building on the broad efficacy previously seen with tezepelumab, this exciting data brings us one step closer to delivering a medicine to severe asthma patients, including those with low eosinophil counts,” he added.

AZ’s own interleukin-5 inhibitor (IL-5) Fasenra (benralizumab) is approved as an add-on maintenance treatment for eosinophilic asthma, while another IL-5 inhibitor from GlaxoSmithKline’s IL-5 Nucala (mepolizumab) is authorised as a treatment for severe asthma associated with elevated eosinophils.

Article by
Lucy Parsons

11th November 2020

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....